A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors

Key Points

177Lu-Dotatate/capecitabine did not improve overall response rate in advanced neuroendocrine tumors, and
Patients receiving combination therapy displayed reduced quality-adjusted life years compared to monotherapy.
The study was a phase II randomized controlled trial assessing treatment effectiveness among advanced neuroendocrine tumors.
Findings suggest that combining capecitabine with 177Lu-Dotatate may not confer additional survival benefits, emphasizing monotherapy.

Abstract

In this prematurely closed phase II study, 177Lu-Dotatate/capecitabine did not improve ORR or prolong PFS and OS in advanced NET patients compared to 177Lu-Dotatate alone and was associated with reduced QALYs.

Bookmark

Cite This Study

Becx et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75b5dc6e9836116a22929 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-25-1884

Bookmark